small-molecule-therapeutics
(5)
Bryan Stuart
Bryan Stuart is the Chief Executive Officer and a director of Atavistik Bio, a Cambridge, Massachusetts biotechnology company building precision allosteric small molecule therapeutics on its Atavistik Metabolite-Protein Screening (AMPS) platform. He joined in July 2023 after more than two decades leading biopharma companies, including roles as CEO of Fulcrum Therapeutics, Yarra Therapeutics, and Kastle Therapeutics. Under his leadership Atavistik has raised a $120 million Series B in December 2025, later extended to $160 million, to advance its lead programs for hereditary hemorrhagic telangiectasia and myeloproliferative neoplasms toward the clinic.
Eddine Saiah
Eddine Saiah, Ph.D., is the CEO and President of Stablix, a preclinical biotechnology company pioneering targeted protein stabilization (TPS) as a new class of small-molecule medicines. A medicinal chemist and drug hunter with more than 25 years of experience, he joined Stablix as Chief Scientific Officer in 2022 and moved into the chief executive role in 2025. His career spans big pharma research leadership at Pfizer and Wyeth, an entrepreneur-in-residence stint at Atlas Venture, and CSO duties at Navitor Pharmaceuticals. He is a co-inventor and author on more than 120 patents and publications, and has helped advance more than a dozen small-molecule candidates into clinical trials.
Scott Greenberg
Scott Greenberg is the Chief Business Officer of Nura Bio, a clinical-stage biopharmaceutical company in South San Francisco building small-molecule drugs to stop nerves from dying. He joined in February 2025 to steer business development and corporate strategy as the company pushes its lead SARM1 inhibitor, NB-4746, into the clinic. He arrives with more than two decades crossing the line between finance and biology - a Goldman Sachs banking start, more than a decade at Celgene, an operations leadership role at Roivant Sciences, and a stint as Chief Operating Officer at Aro Biotherapeutics. He studied both Finance and the Biological Basis of Behavior at the University of Pennsylvania before an MBA at Harvard.
Wenqing Yao
Wenqing Yao is the founder and CEO of Synnovation Therapeutics, a precision-oncology biotech in Wilmington, Delaware. A medicinal chemist by training, he spent nearly two decades at Incyte building and leading its discovery chemistry engine, a stretch that produced five FDA-approved drugs including Jakafi. In 2021 he left to start Synnovation, which launched publicly in January 2024 with a $102 million Series A to advance best-in-class small molecules against highly validated targets, led by a CNS-penetrant, isoform-selective PARP1 inhibitor and a mutant-selective PI3K-alpha inhibitor.
Vishwanath Lingappa
Vishwanath Lingappa is the CEO and CTO of Prosetta Biosciences, a San Francisco-based biotechnology company he founded in 2003 after 22 years as a faculty member at UCSF. An MD-PhD with a doctorate from The Rockefeller University under Nobel laureate Gunter Blobel, Lingappa developed a proprietary Cell-Free Protein Synthesis System (CFPSS) drug discovery platform that targets transient multi-protein complexes - a class of drug targets largely ignored by traditional pharma. His company is pursuing small-molecule therapeutics across neurodegenerative diseases (Alzheimer's, ALS, Parkinson's), oncology, and infectious diseases (COVID-19, HIV, influenza), and won an ARPA-H Dash competition for a pan-cancer drug candidate. With over 157 publications and 12,800+ citations, Lingappa bridges rigorous academia with commercial biotech ambition.